Abigail Koehler

Abigail Koehler

Auto-generated profile, based on publicly available information

Abigail Koehler

University of Cincinnati College of Medicine, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
DBDebanjan Bhattacharya
Debanjan Bhattacharya
VGVaibhavkumar S Gawali
Vaibhavkumar S Gawali
LKLaura Kallay
Laura Kallay
DTDonatien K Toukam
Donatien K Toukam
AKAbigail Koehler
Abigail Koehler
Soma SenguptaSoma Sengupta
Soma Sengupta
γ-aminobutyric acid or GABA is an amino acid that functionally acts as a neurotransmitter and is critical to neurotransmission. GABA is also a metabolite in the Krebs cycle. It is therefore unsurprising that GABA and its receptors are also present outside of the central nervous system, including in immune cells. This observation suggests that GABAergic signaling impacts events beyond brain function and possibly human health beyond neurological disorders. Indeed, GABA receptor subunits are expressed in pathological disease states, including in disparate cancers. The role that GABA and its receptors may play in cancer development and progression remains unclear. If, however, those cancers have functional GABA receptors that participate in GABAergic signaling, it raises an important question whether these signaling pathways might be targetable for therapeutic benefit. Herein we summarize the effects of modulating Type-A GABA receptor signaling in various cancers and highlight how Type-A GABA receptors could emerge as a novel therapeutic target in cancer.

5 January 2022 in Integrative Cancer Therapies
Verified
Journal Article
Open access
PDF file
AKAbigail Koehler
Abigail Koehler
RRRohan Rao
Rohan Rao
YRYehudit Rothman
Yehudit Rothman
YGYair M. Gozal
Yair M. Gozal
TSTimothy Struve
Timothy Struve
Soma SenguptaSoma Sengupta
Soma Sengupta
Chemotherapy-induced thrombocytopenia (CIT) is a critical condition in which platelet counts are abnormally reduced following the administration of chemotherapeutic compounds. CIT poses a treatment conundrum to clinicians given the increased risk of spontaneous bleeding, obstacles to surgical management of tumors, and exclusion from clinical trials. Treatment of CIT involves the removal of the offending agent combined with platelet infusion or thrombopoietin agonist treatment. However, due to the autoimmune and infection risks associated with infusions, this treatment is only reserved for patients with critically low platelet counts. One potential solution for patients in the mid to low platelet count range is Carica papaya leaf extract (CPLE). In this case, we report the novel use of CPLE as a method of bolstering platelet counts in a patient presenting with CIT. The patient was initiated on CPLE therapy consisting of 1 tablespoon twice daily with meals. Following CPLE treatment, the patient’s platelet counts rebounded from less than 10,000/µL to 113,000/µL. This clinical vignette supports the use of CPLE in the clinical context of CIT when thrombopoietin agonists are not a viable option. The potential benefits of CPLE as a method for increasing platelet count deserve further exploration, especially as a treatment option for refractory patients or those ill-suited for other traditional thrombocytopenia therapies.